| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2007 (ast)
- наукова стаття, опублікована у вересні 2007 (uk)
- scientific article published on 10 September 2007 (en)
- 2007 թվականի սեպտեմբերի 10-ին հրատարակված գիտական հոդված (hy)
- مقالة علمية نشرت في 10 سبتمبر 2007 (ar)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| cites work
| |
| cites work
| |
| author name string
| |
| author name string
| - W Jeffrey Fessel
- Tommy F Liu
- Yumi Mitsuya
|
| rdfs:label
| - Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (en)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (nl)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (ast)
|
| skos:prefLabel
| - Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (en)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (nl)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (ast)
|
| name
| - Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (en)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (nl)
- Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| number of pages
| |
| number of pages
| |
| DOI
| |
| DOI
| |
| DOI
| |
| Fatcat ID
| |
| Fatcat ID
| - release_j542qkwhbnbv7cgiki7i5odesm
|
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| PMCID
| |
| PMCID
| |
| is about
of | |
| is cites work
of | - In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
- A Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIV
- The L76V Drug Resistance Mutation Decreases the Dimer Stability and Rate of Autoprocessing of HIV-1 Protease by Reducing Internal Hydrophobic Contacts
- Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
- P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety
- Darunavir
- A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes
- Management of HIV infection in treatment-naive patients: a review of the most current recommendations
- US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial
- Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
- Darunavir: a review of its use in the management of HIV-1 infection
- Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
- Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants
- Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
- Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing
- Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers
- Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies
- A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)